Key facts
- AtaCor Medical’s last known valuation is $80.0M (Apr 2024).
- It has raised $148.9M; the latest was Later Stage VC ($75.0M) in Oct 2025.
- Notable investors include MedTech Innovator, Hatteras Venture Partners, Arboretum Ventures, Sea Purity Investments, BayMed Venture Partners — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for AtaCor Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for AtaCor Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AtaCor Medical
Developer of cardiac pacing and defibrillation leads, and associated delivery tools designed to provide alternatives to traditional devices. The company offers completely extravascular pacing and defibrillation lead systems to reduce procedural complications and improve patient safety, enabling healthcare providers to offer more versatile and less invasive options for their patients.
- Sector
- Healthcare
- HQ
- San Clemente, CA, United States
- Founded
- 2014
- Employees
- 24
- Website
- atacor.com/
- Ownership
- Privately Held (backing)
AtaCor Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AtaCor Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AtaCor Medical in its N-PORT filings yet. We sweep new filings monthly.